Andrew J. Fromkin is Director at Immunovant, Inc. (IMVT). They have made 2 open-market trades across 1 company since 2021, most recently 2026-05-28.
1 open-market purchase totalling $43K since 2021, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| IMVT | 74,382 | $2.0M |
Shares reported on the most recent Form 4, priced at the 2026-05-29 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| IMVT | SELL | 2026-05-28 | 2026-05-29 | $33.51 | $7.4M | -4.8% | +17.7% | +33.8% |
| IMVT | SELL · 10b5-1 | 2025-12-01 | 2025-12-03 | $23.25 | $1.0M | +15.3% | +14.9% | +18.4% |
| IMVT | SELL · 10b5-1 | 2025-03-07 | 2025-03-11 | $19.56 | $286K | -0.3% | -24.9% | -17.3% |
| IMVT | SELL · 10b5-1 | 2023-12-01 | 2023-12-05 | $39.73 | $981K | +7.8% | -1.9% | -12.4% |
| IMVT | BUY | 2021-08-10 | 2021-08-11 | $7.90 | $43K | +1.7% | +5.5% | +9.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.